Bristol-Myers Squibb
BMY | NYSE
$62.48
+$1.09 (+1.78%)
At close: Oct 30, 2026, 4:00 PM ET
$62.55
+$0.07 (+0.11%)
After-hours:
Oct 30, 2026, 7:31 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 48.2B | 48.3B | 45.01B | 46.16B | 46.39B | 42.52B |
Cost of Revenue | 13.94B | 13.97B | 10.69B | 10.14B | 9.94B | 11.77B |
Gross Profit | 34.26B | 34.33B | 34.31B | 36.02B | 36.45B | 30.75B |
Operating Income | 13.72B | 5.89B | 8.2B | 9.1B | 8.54B | 2.18B |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 9.33B | -8.38B | 8.44B | 7.71B | 8.1B | -6.87B |
Net Income | 7.05B | -8.95B | 8.03B | 6.33B | 6.99B | -9.02B |
Selling & General & Admin | 7.27B | 8.41B | 7.77B | 7.81B | 7.69B | 7.66B |
Research & Development | 9.95B | 11.16B | 9.3B | 9.51B | 10.2B | 11.14B |
Other Expenses | 3.32B | 8.87B | 9.05B | 9.6B | 10.02B | 9.76B |
Operating Expenses | 20.54B | 28.45B | 26.12B | 26.92B | 27.91B | 28.57B |
Interest Expense | 1.89B | 1.95B | 1.17B | 1.23B | 1.33B | 1.42B |
Selling & Marketing Expenses | n/a | n/a | n/a | 7.81B | 7.69B | 7.66B |
Cost & Expenses | 34.47B | 42.41B | 36.81B | 37.06B | 37.85B | 40.34B |
Income Tax Expense | 2.27B | 554M | 400M | 1.37B | 1.08B | 2.12B |
Shares Outstanding (Basic) | 2.04B | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B |
Shares Outstanding (Diluted) | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B |
EPS (Basic) | 3.46 | -4.41 | 3.88 | 2.97 | 3.15 | -3.98 |
EPS (Diluted) | 3.45 | -4.41 | 3.86 | 2.95 | 3.12 | -3.98 |
EBITDA | 15.23B | 3.17B | 19.37B | 19.22B | 20.12B | 4.93B |
EBIT | 11.22B | -6.43B | 9.61B | 8.95B | 9.43B | -5.45B |
Depreciation & Amortization | 4.01B | 9.6B | 9.76B | 10.28B | 10.69B | 10.38B |
Add to Watchlist
Select watchlists to add or remove BMY